Octapharma

This study tests a medicine called Atenativ, made from a natural blood protein, in people having heart surgery. Some patients don't respond well to the standard blood thinner heparin, which can cause complications. The trial will see if Atenativ helps restore heparin's effect, ma…

This study tests a medicine called OCTAPLEX to stop serious bleeding in people taking blood thinners (factor Xa inhibitors). About 260 participants will receive either a low or high dose to see which works better and is safer. The goal is to control bleeding quickly and reduce co…

This study tests a drug called Atenativ in people with a rare inherited condition that raises their risk of dangerous blood clots. The goal is to see if the drug can prevent clots during surgery or childbirth. About 38 adults and teens will take part, and researchers will monitor…

This study observes how well Octapharma's FVIII concentrates (Nuwiq, Octanate, Wilate) work in real life for people with severe hemophilia A who have had little or no prior treatment. Researchers will track bleeding events and side effects over time. The goal is to understand the…

This study tests whether a clotting factor called Nuwiq can safely prevent bleeding during major surgery in people with severe hemophilia A who are already taking another drug (emicizumab) to prevent bleeds. About 28 male patients aged 12 and older will receive Nuwiq around the t…

This study tests a medicine called Nuwiq to prevent bleeding during major surgery in women and girls with hemophilia A. About 28 participants will receive the treatment, and doctors will check if it works well. The goal is to manage bleeding, not to cure the condition.

This study tests an intravenous drug (C1 esterase inhibitor) in people with hereditary angioedema (HAE) to see if it can quickly relieve swelling attacks and prevent them before medical procedures. About 124 adults and children with HAE type I or II will receive either the drug o…